Global EconomyShould you buy, sell or hold? What brokerage says, target price•1 min read•11/2/2026 (3h ago)
Sun Pharma shares gain despite Q2 profit slips 36% YoY
60-Word AI Digest
Sun Pharma shares rose 0.87% despite a 36.4% year-on-year drop in September-quarter net profit to ₹1,988.5 crore. Revenue increased 11.9% to ₹16,198.7 crore, driven by India and innovative medicines, while exceptional US litigation and Organon acquisition costs weighed on earnings.
Key Takeaways
- Sun Pharma shares rose 0.87% despite a 36.4% year-on-year drop in September-quarter net profit to ₹1,988.5 crore.
- Revenue increased 11.9% to ₹16,198.7 crore, driven by India and innovative medicines, while exceptional US litigation and Organon acquisition costs weighed on earnings.
- Full details and original dispatch available below.
Sun Pharma shares rose 0.87% despite a 36.4% year-on-year drop in September-quarter net profit to ₹1,988.5 crore. Revenue increased 11.9% to ₹16,198.7 crore, driven by India and innovative medicines, while exceptional US litigation and Organon acquisition costs weighed on earnings.
Original Publisher Attribution
This summary was curated from Should you buy, sell or hold? What brokerage says, target price.